Dr. John Babich

Dr. John Babich earned his PhD in Radiopharmaceutical Chemistry from the Institute of Cancer Research at the University of London in 1994. He has over 30 years of experience in radiopharmaceutical sciences and nuclear medicine, spanning academic, clinical, and biotech/pharma settings. His scientific career began with training at Brookhaven National Lab and Baylor College of Medicine in the early 1980s. He held academic positions at Harvard Medical School and Weill Cornell Medical College (WMC). His hospital experience includes roles as a radiopharmaceutical chemist at Massachusetts General Hospital and professor and chief of radiopharmaceutical sciences at NewYork-Presbyterian Hospital/WMC. Dr. Babich was also president and chief scientific officer of Molecular Insight Pharmaceuticals for 15 years. Currently, he is president and chief scientific officer at Ratio Therapeutics which he co-founded in 2021. His research has focused on developing radiolabeled small molecules for cancer imaging and therapy. He has particular expertise in prostate cancer, leading the translation of PSMA-targeted radioligands from bench to bedside. Dr. Babich has co-authored over 230 peer-reviewed papers and is an inventor on over 50 patents. His contributions have been recognized with several prestigious awards.